/
Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molec…
$72.12
+$0.35 (+0.49%)
EOD Jul 17, 2026
Operating margin is thin at 8.38%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.2%, steady but not accelerating. Margins contracted 9.4pp, which offsets some of the top-line progress.
At 105x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 7.70% to 3.18%, capital efficiency is deteriorating.
104.5x earnings, 42.1x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.21B
▲ +5.2% YoY
Net Income (TTM)
$110M
▼ -56.3% YoY
Op. Margin
12.70%
▼ -9.4pp YoY
ROIC
4.91%
▼ -4.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$270M
▲ +8.7% YoY
Op. Cash Flow (TTM)
$295M
▼ -3.8% YoY
Net Debt
$81M
Cash & Equiv.
$210M
5Y CAGR: +10.5%
5Y CAGR: +10.8%
Continue Research
At a P/E of 104.5 and a price-to-free-cash-flow of 42.1, Bio-Techne (TECH) trades above a two-stage DCF intrinsic value of about $29.17 per share, so at $72.12 the stock looks overvalued (59.6% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bio-Techne scores 37/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $29.17 per share for TECH, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $21.88. At today's $72.12, that puts the stock about 59.6% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Bio-Techne scores 37 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 12.7% operating margin and a 4.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Bio-Techne pays a regular dividend of about $0.32 per share per year (typically in quarterly installments), a yield of roughly 0.4% at the current price. That is a payout ratio of about 45.5% of earnings, so the dividend is well covered. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For TECH's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. TECH currently trades above its estimated intrinsic value and scores 37/100 on quality (lower-quality). It also yields about 0.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.